| Introduction of p27(Kip1) is haploinsufficient for ErbB2 mammary tumor suppression in vivo and functions to repress collaborative oncogenic signals. | None |
| Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. | breast, |
| Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. | esophageal, |
| The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. | breast, |
| Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. | breast,ovarian, |
| Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67. | gastric, |
| c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors. | ovarian, |
| Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. | prostate, |
| Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. | colorectal, |
| HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. | ovarian, |
| Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. | prostate, |
| Correlation between EGFR and c-erbB-2 oncoprotein status and response to neoadjuvant chemotherapy in cervical carcinoma. | cervical, |
| [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?]. | breast, |
| The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. | gastric, |
| HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. | cervical, |
| The c-erbB-2 oncogene amplification by competitive PCR in aneuploid cell clones flow sorted from breast cancer samples. | breast, |
| Involvement of the c-erbB-2 oncogene product in the EGF-induced cell motility of SK-OV-3 ovarian cancer cells. | ovarian, |
| Detection by immunohistochemistry of c-erbB2 oncoprotein in breast carcinomas and benign mammary lesions. | breast, |
| Gastric carcinoma: expression of c-erbB-2/neu oncoprotein, epidermal growth factor receptor, cathepsin D, progesterone receptor and tumor associated glycoprotein-72 in different histological types. | gastric, |
| Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. | breast, |